echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Transl Lung Cancer Res: Influence of previous thoracic radiotherapy (RT) on the efficacy of anlotinib in patients with recurrent small cell lung cancer (SCLC)

    Transl Lung Cancer Res: Influence of previous thoracic radiotherapy (RT) on the efficacy of anlotinib in patients with recurrent small cell lung cancer (SCLC)

    • Last Update: 2022-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial ALTER 1202 Shows that anlotinib Extends Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Relapsed Small Cell Lung Cancer
    (SCLC) .


    The results of a subgroup analysis of the ALTER 1202 study were recently published in the journal Translational Lung Cancer Research to assess the effect of prior thoracic radiotherapy (RT) on the efficacy of anlotinib in patients with recurrent small cell lung cancer (SCLC)


    Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial ALTER 1202 Shows that anlotinib Extends Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Relapsed Small Cell Lung Cancer


    The study divided patients into two groups: RT group and non-RT group
    .


    Study endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety


    The study divided patients into two groups: RT group and non-RT group


    In the ALTER 1202 trial, 68 patients (anlotinib, n=46; placebo, n=22) had previously received RT and 51 patients (anlotinib, n=35; placebo, n=16) had not received RT


    In the RT subgroup, median PFS was 5.


    In the Cox analysis, adjusted for disease stage and recurrence pattern, the use of anlotinib in both the RT group (HR 0.
    13; 95% CI: 0.
    06-0.
    28) and the non-RT subgroup (HR 0.
    16; 95% CI: 0.
    07-0.
    38) associated with prolonged PFS
    .


    In the anlotinib arm, RT was associated with progression-free survival (PFS) when adjusted for disease stage and recurrence pattern (HR 0.


    In the Cox analysis, adjusted for disease stage and recurrence pattern, the use of anlotinib in both the RT group (HR 0.


    In the RT subgroup, median OS was 9.


    In the Cox analysis, when adjusted for disease stage and recurrence pattern, use of anlotinib was associated with OS in the RT subgroup (HR 0.
    47; 95% CI: 0.
    22-0.
    98), but not in the non-RT subgroup (HR 0.
    54; 95%CI: 0.
    22-1.
    33)
    .


    In the anlotinib arm, RT was not significantly associated with OS when adjusted for disease stage and recurrence pattern (HR 0.


    In the Cox analysis, when adjusted for disease stage and recurrence pattern, use of anlotinib was associated with OS in the RT subgroup (HR 0.


    There was no significant difference in ORR between the two treatments in the RT subgroup (P=0.


    Taken together, the study demonstrated DCR, PFS, and OS benefits with anlotinib compared with placebo in patients with relapsed SCLC who had previously received thoracic radiotherapy
    .
    In patients without prior thoracic radiation therapy, DCR and PFS benefited with anlotinib compared with placebo
    .

    Taken together, the study demonstrated DCR, PFS, and OS benefits with anlotinib compared with placebo in patients with relapsed SCLC who had previously received thoracic radiotherapy
    .
    In patients without prior thoracic radiation therapy, DCR and PFS benefited with anlotinib compared with placebo
    .
    The study demonstrated DCR, PFS, and OS benefits with anlotinib compared with placebo in patients with relapsed SCLC who had previously received thoracic radiotherapy
    .
    In patients without prior thoracic radiation therapy, DCR and PFS benefited with anlotinib compared with placebo
    .
    The study demonstrated DCR, PFS, and OS benefits with anlotinib compared with placebo in patients with relapsed SCLC who had previously received thoracic radiotherapy
    .
    In patients without prior thoracic radiation therapy, DCR and PFS benefited with anlotinib compared with placebo
    .

    Original source:

    Original source:

    Liu Y, Cheng Y, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Qin H, Li X, Hamaji M, Park HS.
    Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial.
    Transl Lung Cancer Res 2021;10(9):3793-3806.
    doi: 10.
    21037/tlcr-21-632

    Liu Y, Cheng Y, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Qin H, Li X, Hamaji M, Park HS.
    Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial.
    Transl Lung Cancer Res 2021;10(9):3793-3806.
    doi: 10.
    21037/tlcr-21-632 Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.